Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Collaborators: The Cleveland Clinic; University of Illinois at Chicago
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

1. Patients with vision-threatening autoimmune uveitis.

2. Failure to respond to prednisone and at least one other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects.

Exclusion Criteria:

1. Serious concomitant illness that could interfere with the subject's participation in the trial.

2. Previous or current use of cyclophosphamide.

3. Unable or unwilling to undergo multiple injections.